Adverse Event Management in Colorectal Cancer: Optimizing Treatment Approaches in the 3L Setting : Episode 5

Opinion

Video

April 11, 2024

Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC

A panel of experts on colorectal cancer have a comprehensive discussion on adverse events associated with TAS-102 plus bevacizumab and strategies to mitigate them.

EP: 1.Adverse Event Management in Colorectal Cancer: Optimizing Treatment Approaches in the 3L Setting

EP: 2.Selecting Optimal 3L Colorectal Cancer Treatment

EP: 3.Patient Case 1: 46-Year-Old Woman with Prior Hx of MSS pT4aN1b Rectosigmoid Colon Adenocarcinoma s/p Prior Treatment

EP: 4.General Approach to 3L CRC Treatment with TAS-102 + Bevacizumab

Now Viewing

EP: 5.Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC

EP: 6.Patient Case 2: A 62-Year-Old Woman with Metastatic Rectal Cancer

EP: 7.Treatment Considerations With Regorafenib in Colorectal Cancer

EP: 8.Patient Case 3: A 57-Year-Old Man With Cecal Colon Adenocarcinoma

EP: 9.FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC

EP: 10.Monitoring and AE Management Strategies with Fruquintinib in CRC

EP: 11.Toxicity Considerations and Treatment Decisions in CRC

EP: 12.Multidisciplinary Care for Patients with CRC

EP: 13.Unmet Needs and Future Perspectives in Colorectal Cancer

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Related Content

March 21st 2025

Improving Outcomes for Patients With Anal Cancer By Raising Awareness

September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

March 19th 2025

FDA Approves Pembrolizumab Plus Trastuzumab/Chemo for PD-L1+, HER2+ Gastric/GEJ Adenocarcinoma

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS

May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

March 19th 2025

Association Between CLDN18 and MUC1 Could Drive Novel Targeted Therapy Options in GI Cancers

Ajay Goel, PhD, AGAF, professor, chair, Department of Molecular Diagnostics and Experimental Therapeutics at City of Hope in Duarte, California

March 19th 2025

CA19-9 Plus Liquid Biopsy Represents Diagnostic Biomarker of Interest for Early-Stage Pancreatic Cancer Detection

Related Content

March 21st 2025

Improving Outcomes for Patients With Anal Cancer By Raising Awareness

September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

March 19th 2025

FDA Approves Pembrolizumab Plus Trastuzumab/Chemo for PD-L1+, HER2+ Gastric/GEJ Adenocarcinoma

May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

March 19th 2025

Association Between CLDN18 and MUC1 Could Drive Novel Targeted Therapy Options in GI Cancers

March 19th 2025

CA19-9 Plus Liquid Biopsy Represents Diagnostic Biomarker of Interest for Early-Stage Pancreatic Cancer Detection

Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC

EP: 1.Adverse Event Management in Colorectal Cancer: Optimizing Treatment Approaches in the 3L Setting

EP: 2.Selecting Optimal 3L Colorectal Cancer Treatment

EP: 3.Patient Case 1: 46-Year-Old Woman with Prior Hx of MSS pT4aN1b Rectosigmoid Colon Adenocarcinoma s/p Prior Treatment

EP: 4.General Approach to 3L CRC Treatment with TAS-102 + Bevacizumab

EP: 5.Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC

EP: 6.Patient Case 2: A 62-Year-Old Woman with Metastatic Rectal Cancer

EP: 7.Treatment Considerations With Regorafenib in Colorectal Cancer

EP: 8.Patient Case 3: A 57-Year-Old Man With Cecal Colon Adenocarcinoma

EP: 9.FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC

EP: 10.Monitoring and AE Management Strategies with Fruquintinib in CRC

EP: 11.Toxicity Considerations and Treatment Decisions in CRC

EP: 12.Multidisciplinary Care for Patients with CRC

EP: 13.Unmet Needs and Future Perspectives in Colorectal Cancer

Newsletter

Latest Conference Coverage